Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1964 1
1965 3
1967 3
1968 2
1969 2
1970 3
1971 1
1972 3
1973 3
1974 4
1975 1
1976 2
1977 3
1978 4
1979 3
1980 2
1981 5
1983 1
1984 3
1985 3
1986 6
1987 4
1988 1
1989 3
1991 4
1992 2
1993 3
1994 3
1995 1
1996 2
1997 1
1999 1
2000 1
2002 1
2004 1
2005 2
2006 2
2007 4
2008 4
2009 4
2010 1
2011 3
2012 6
2014 2
2015 5
2016 2
2017 7
2018 12
2019 13
2020 10
2021 10
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

176 results
Results by year
Filters applied: . Clear all
Page 1
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Wang DY, et al. Among authors: davis ej. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. JAMA Oncol. 2018. PMID: 30242316 Free PMC article.
Hematologic Complications of Immune Checkpoint Inhibitors.
Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB. Davis EJ, et al. Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28. Oncologist. 2019. PMID: 30819785 Free PMC article.
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Patrinely JR Jr, et al. Among authors: davis ej. JAMA Oncol. 2021 May 1;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051. JAMA Oncol. 2021. PMID: 33764387 Free PMC article.
Toxicities Associated With PD-1/PD-L1 Blockade.
Wang DY, Johnson DB, Davis EJ. Wang DY, et al. Among authors: davis ej. Cancer J. 2018 Jan/Feb;24(1):36-40. doi: 10.1097/PPO.0000000000000296. Cancer J. 2018. PMID: 29360726 Free PMC article. Review.
Melanoma: What do all the mutations mean?
Davis EJ, Johnson DB, Sosman JA, Chandra S. Davis EJ, et al. Cancer. 2018 Sep 1;124(17):3490-3499. doi: 10.1002/cncr.31345. Epub 2018 Apr 17. Cancer. 2018. PMID: 29663336 Free PMC article. Review.
Photothermal Heating and Cooling of Nanostructures.
Crane MJ, Zhou X, Davis EJ, Pauzauskie PJ. Crane MJ, et al. Among authors: davis ej. Chem Asian J. 2018 Sep 17;13(18):2575-2586. doi: 10.1002/asia.201800251. Epub 2018 Aug 17. Chem Asian J. 2018. PMID: 29890034 Review.
Machine learning for rhabdomyosarcoma histopathology.
Frankel AO, Lathara M, Shaw CY, Wogmon O, Jackson JM, Clark MM, Eshraghi N, Keenen SE, Woods AD, Purohit R, Ishi Y, Moran N, Eguchi M, Ahmed FUA, Khan S, Ioannou M, Perivoliotis K, Li P, Zhou H, Alkhaledi A, Davis EJ, Galipeau D, Randall RL, Wozniak A, Schoffski P, Lee CJ, Huang PH, Jones RL, Rubin BP, Darrow M, Srinivasa G, Rudzinski ER, Chen S, Berlow NE, Keller C. Frankel AO, et al. Among authors: davis ej. Mod Pathol. 2022 Sep;35(9):1193-1203. doi: 10.1038/s41379-022-01075-x. Epub 2022 Apr 21. Mod Pathol. 2022. PMID: 35449398
The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.
Stormo AED, Shavarebi F, FitzGibbon M, Earley EM, Ahrendt H, Lum LS, Verschueren E, Swaney DL, Skibinski G, Ravisankar A, van Haren J, Davis EJ, Johnson JR, Von Dollen J, Balen C, Porath J, Crosio C, Mirescu C, Iaccarino C, Dauer WT, Nichols RJ, Wittmann T, Cox TC, Finkbeiner S, Krogan NJ, Oakes SA, Hiniker A. Stormo AED, et al. Among authors: davis ej. J Cell Biol. 2022 Apr 4;221(4):e202010065. doi: 10.1083/jcb.202010065. Epub 2022 Mar 10. J Cell Biol. 2022. PMID: 35266954 Free PMC article.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Gounder MM, et al. Among authors: davis ej. J Clin Oncol. 2022 Aug 1;40(22):2479-2490. doi: 10.1200/JCO.21.01829. Epub 2022 Apr 8. J Clin Oncol. 2022. PMID: 35394800 Free PMC article. Clinical Trial.
176 results